Diamide compounds having muscarinic receptor antagonist and β
The invention provides diamide compounds having muscarinic receptor antagonist and β 2 adrenergic receptor agonist activity, pharmaceutical compositions thereof, and methods of treatment using the same.
1. A compound of the formula:
or a pharmaceutically acceptable salt thereof.
2. A pharmaceutical composition comprising
(a) a compound of claim 1 , or a pharmaceutically acceptable salt thereof; and
(b) a pharmaceutically acceptable carrier.
3. A pharmaceutical composition comprising
(a) a compound of claim 1 , or a pharmaceutically acceptable salt thereof;
(b) a steroidal anti-inflammatory agent or a pharmaceutically acceptable salt or solvate thereof; and
(c) a pharmaceutically acceptable carrier.
4. The pharmaceutical composition of claim 3 , wherein the steroidal anti-inflammatory agent is a corticosteroid or a pharmaceutically acceptable salt or solvate thereof.
5. A method for treating a pulmonary disorder in a patient comprising administering to the patient a compound of claim 1 or a pharmaceutically acceptable salt thereof.
6. A method for treating a pulmonary disorder in a patient comprising:
(a) administering to the patient a compound of claim 1 , or a pharmaceutically acceptable salt thereof; and
(b) administering to the patient a steroidal anti-inflammatory agent, or a pharmaceutically acceptable salt or solvate thereof;
wherein step (a) and (b) are conducted simultaneously or sequentially in any order.
7. The method of claim 5 , wherein the pulmonary disorder is chronic obstructive pulmonary disease.
8. The method of claim 5 , wherein the pulmonary disorder is asthma.
9. A method for producing bronchodilation in a mammal comprising administering to the mammal a bronchodilation-producing amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.
10. The method of claim 9 , wherein the mammal is a human.
11. A compound of the formula:
or a pharmaceutically acceptable salt thereof.
12. A pharmaceutical composition comprising
(a) a compound of claim 11 , or a pharmaceutically acceptable salt thereof; and
(b) a pharmaceutically acceptable carrier.
13. A pharmaceutical composition comprising
(a) a compound of claim 11 , or a pharmaceutically acceptable salt thereof;
(b) a steroidal anti-inflammatory agent or a pharmaceutically acceptable salt or solvate thereof; and
(c) a pharmaceutically acceptable carrier.
14. The pharmaceutical composition of claim 13 , wherein the steroidal anti-inflammatory agent is a corticosteroid or a pharmaceutically acceptable salt or solvate thereof.
15. A method for treating a pulmonary disorder in a patient comprising administering to the patient a compound of claim 11 or a pharmaceutically acceptable salt thereof.
16. A method for treating a pulmonary disorder in a patient comprising:
(a) administering to the patient a compound of claim 11 , or a pharmaceutically acceptable salt thereof; and
(b) administering to the patient a steroidal anti-inflammatory agent, or a pharmaceutically acceptable salt or solvate thereof;
wherein step (a) and (b) are conducted simultaneously or sequentially in any order.
17. The method of claim 15 , wherein the pulmonary disorder is chronic obstructive pulmonary disease.
18. The method of claim 15 , wherein the pulmonary disorder is asthma.
19. A method for producing bronchodilation in a mammal comprising administering to the mammal a bronchodilation-producing amount of a compound of claim 11 , or a pharmaceutically acceptable salt thereof.
20. The method of claim 19 , wherein the mammal is a human.
21. A compound of the formula:
or a pharmaceutically acceptable salt thereof.
22. A pharmaceutical composition comprising
(a) a compound of claim 21 , or a pharmaceutically acceptable salt thereof; and
(b) a pharmaceutically acceptable carrier.
23. A pharmaceutical composition comprising
(a) a compound of claim 21 , or a pharmaceutically acceptable salt thereof;
(b) a steroidal anti-inflammatory agent or a pharmaceutically acceptable salt or solvate thereof; and
(c) a pharmaceutically acceptable carrier.
24. The pharmaceutical composition of claim 23 , wherein the steroidal anti-inflammatory agent is a corticosteroid or a pharmaceutically acceptable salt or solvate thereof.
25. A method for treating a pulmonary disorder in a patient comprising administering to the patient a compound of claim 21 or a pharmaceutically acceptable salt thereof.
26. A method for treating a pulmonary disorder in a patient comprising:
(a) administering to the patient a compound of claim 21 , or a pharmaceutically acceptable salt thereof; and
(b) administering to the patient a steroidal anti-inflammatory agent, or a pharmaceutically acceptable salt or solvate thereof;
wherein step (a) and (b) are conducted simultaneously or sequentially in any order.
27. The method of claim 25 , wherein the pulmonary disorder is chronic obstructive pulmonary disease.
28. The method of claim 25 , wherein the pulmonary disorder is asthma.
29. A method for producing bronchodilation in a mammal comprising administering to the mammal a bronchodilation-producing amount of a compound of claim 21 , or a pharmaceutically acceptable salt thereof.
30. The method of claim 29 , wherein the mammal is a human.